SCHEMBL17242018

SCHEMBL17242018

Cc1ccccc1-c1ccc2c3ccc(-c4ccccc4C)c4cccc(c5cccc1c52)c43

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2A6 P11509 2/20 0.44
CYP1A2 P05177 2/20 0.44
ALDH1A1 P00352 3/20 0.43
KDM4E B2RXH2 3/20 0.43
SMN1; SMN2 Q16637 2/20 0.43
BRD4 O60885 1/20 0.43
MAPT P10636 1/20 0.43
PABPC1 P11940 1/20 0.43
KIF11 P52732 1/20 0.39
TSHR P16473 2/20 0.38
CRHBP P24387 1/20 0.38
CRHR2 Q13324 1/20 0.38
KEAP1 Q14145 1/20 0.38
NFE2L2 Q16236 1/20 0.38
ACHE P22303 1/20 0.38
NPC1 O15118 1/20 0.38
CASP3 P42574 1/20 0.38
RAB9A P51151 1/20 0.38
SENP8 Q96LD8 1/20 0.38
SENP7 Q9BQF6 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17241899 1.00 CYP2A6 (0.44) CYP2A6CYP1A2ALDH1A1KDM4ESMN1; SMN2
SCHEMBL2182429 0.87 PABPC1 (0.56) CYP2A6CYP1A2ALDH1A1KDM4ESMN1; SMN2
SCHEMBL16801034 0.84 SMN1; SMN2 (0.41) CYP2A6CYP1A2ALDH1A1KDM4ESMN1; SMN2
SCHEMBL22978748 0.82 CYP1A2 (0.48) CYP2A6CYP1A2ALDH1A1KDM4ESMN1; SMN2
SCHEMBL2447864 0.80 CYP1A2 (0.46) CYP2A6CYP1A2ALDH1A1KDM4ESMN1; SMN2
SCHEMBL29444830 0.80 CYP1A2 (0.46) CYP2A6CYP1A2ALDH1A1KDM4ESMN1; SMN2
SCHEMBL5949488 0.77 BRD4 (0.41) CYP2A6CYP1A2ALDH1A1KDM4ESMN1; SMN2
SCHEMBL2996863 0.77 CYP2A6 (0.65) CYP2A6CYP1A2ALDH1A1KDM4EBRD4
SCHEMBL2328517 0.77 ALDH1A1 (0.48) CYP2A6CYP1A2ALDH1A1KDM4ETSHR
SCHEMBL10410108 0.77 CYP1A2 (0.52) CYP2A6CYP1A2ALDH1A1KDM4ESMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3140268-B1 CYANATED PERYLENE COMPOUNDS BASF SE (DE) 2018-07-18 EP disclosed
US-9919999-B2 Cyanated perylene compounds BASF SE (DE) 2018-03-20 US disclosed
US-20170183295-A1 CYANATED PERYLENE COMPOUNDS BASF SE (DE) 2017-06-29 US disclosed
EP-3140268-A1 CYANATED PERYLENE COMPOUNDS BASF SE (DE) 2017-03-15 EP disclosed
WO-2015169935-A1 CYANATED PERYLENE COMPOUNDS BASF SE (DE) 2015-11-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170183295-A1 CYANATED PERYLENE COMPOUNDS C1R, C9, CBR1 CYP2A6 1991/4885CYP1A2 618/4885ALDH1A1 1647/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.